LUMOS DIAGNOSTICS

Commercial Operations Update

December 2023

www.lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Commercial Update – US Launch of ViraDx™ and FebriDx®

AGENDA

- Overview of Products
- US Sales Channel Update
- Production Update
- ViraDx – US Commercial Update
- FebriDx – US Commercial Update
- Questions

FebriDx – Lumos' POC test to aid antibiotic prescribing

- **FebriDx is an aid for healthcare providers to improve patient care and antibiotic stewardship**
  - FebriDx is a rapid, lateral flow, POC test that assists with differentiating between bacterial and non-bacterial infections
  - Very effective at ruling out bacterial infections — 98.7% NPV (negative predictive value) for bacterial infections
  - FebriDx provides a visual result within 10 minutes from a single drop of blood
  - Patients who do not have a bacterial infection will not get any benefit from taking antibiotics
  - Taking antibiotics can result in adverse patient reactions and contribute to antimicrobial drug resistance
  - 40% antibiotics prescribed in for respiratory infections unnecessary (ie. patient had no bacterial infection)[1]
- **FebriDx regulatory and commercial update**
  - FebriDx previously cleared in Europe, UK, Australia, Canada and other markets.
  - FDA clearance to market FebriDx as an aid in differentiating bacterial from non-bacterial acute respiratory infections awarded in June 2023
  - Achieved production and sales channel goals to enable commercial launch by end of CY 2023

[1] Tse, J.; Near, A.M.; Cheng, M.; Karichu, J.; Lee, B.; Chang, S.N. Outpatient Antibiotic and Antiviral Utilization Patterns in Patients Tested for Respiratory Pathogens in the United States: A Real-World Database Study. Antibiotics 2022, 11, 1058. https://doi.org/10.3390/ antibiotics11081058

ViraDx™ – Lumos' POC test for key respiratory infections

- **ViraDx highly relevant POC test for post-pandemic environment:**
  - SARS-CoV-2 pandemic increased consumer and healthcare POC testing
  - ViraDx is a 3-in-1 test for COVID-19/'flu A/'flu B
  - One of two tests available in market that provides visual read-out

- **ViraDx regulatory and commercial update:**
  - US EUA awarded in September 2023
  - CLIA waived – able be used in 260,000 clinics in the US

Production

- **Commercialisation activities for FebriDx and ViraDx previously on hold:**
  - Timing and likelihood of US regulatory clearances uncertain
  - Need to conserve cash reserves
  - Commenced commercial scale up activities in July 2023

- **Established commercial production to meet initial anticipated demand**
  - Sourced and ordered inventory of raw material
  - Established assembly and quality testing for both ViraDx and FebriDx
  - Finished product on the shelf ready for shipping
  - Aim to build out to 2-3 months inventory once market demand and seasonality is better understood

Lumos' US Sales Channel

- **Established low-cost, high-reach US sales channel:**
  - Internal Commercial Operations Team:
    - Senior VP Commercial Operations, 4 direct reports
  - Eight Independent Commission-only sales representatives appointed
  - Distributors:
    - Over ten regional distributors appointed (Eg. Atlantic Medical Solutions, CLIA Waived, Inc, Mercedes Scientific, etc)
    - In discussions with large national distributors (Eg. Henry Schein, Fisher etc)
- **Building a product portfolio for the kit bag:**
  - Own products: ViraDx and FebriDx
  - In-licensed: Binx IO: CLIA-waived molecular test for chlamydia & gonorrhoea.
  - Will In-license additional products relevant to urgent care and physician office groups

ViraDx – US Commercial Update

- **Positive market dynamics:**
  - POC testing for respiratory infections well-established in US
  - CDC reporting harsh influenza season this year with outpatient respiratory illness continuing to track above baseline (season continues until March)

- **Sales of ViraDx in the US have commenced:**
  - First test lot released 21 November
  - Pre-orders received and initial stocking orders have been shipped
  - Approximately US$150,000 sales revenue to date
  - Reimbursement — coding is established and has been confirmed
  - Eight distributor agreements executed targeting primary care, urgent care, employee health and student health
  - Expansion plan includes and additional 8 distributor agreements

FebriDx – US Commercial Update

- **Global threat of Antimicrobial Resistance (AMR) gaining attention:**
  - World AMR Awareness Week just finished (18-24 Nov)
  - Recognised overprescribing of antibiotics one of the key drivers of AMR

- **On track for sales to commence by year end:**
  - Pre-orders for FebriDx already received
  - First test lot expected to be released late December
  - Nine distributor agreements executed
  - Expansion plan includes additional 2-3 agreements from majors
  - Currently limited to use in CLIA moderately complex settings:
    - Large urgent care clinics
    - Outpatient clinics

FebriDx – US Commercial Launch Activities

- **CLIA status:**
  - Currently can be used in CLIA Moderately Complex Settings (10,000 labs)
  - Multiple paths to securing CLIA Waiver (260,000 clinical settings)

- **Reimbursement:**
  - Two biomarker CPT codes identified – need to be tested
  - American Medical Association approved Proprietary Laboratory Analyses (PLA) code

- **Marketing and education:**
  - Microbial testing prior to prescribing antibiotics not currently routine
  - Assembling Medical Advisory Board of Urgent Care experts
  - Program of communication through social media and KOLs

US FebriDx Marketing Activities — Overview





Questions